When considering what names to put on your watch list, focus on stocks with an 80 or higher RS Rating. Apogee Therapeutics just met that criteria with a new score of 83.
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 as they launch their biggest price moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
While now is not an ideal time to jump in, see if the stock goes on to offer and clear a proper buy point.
The company posted 0% EPS growth last quarter, while sales growth came in at 0%.
Apogee Therapeutics earns the No. 233 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Corcept Therapeutics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
